• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.17% Nasdaq Up1.27%

    Acceleron Pharma, Inc. (XLRN)

    33.60 Down 0.16(0.47%) Apr 20, 4:00PM EDT
    |After Hours : 33.60 0.00 (0.00%) Apr 20, 5:23PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Acceleron Pharma, Inc.
    128 Sidney Street
    Cambridge, MA 02139
    United States - Map
    Phone: 617-649-9200
    Fax: 617-649-9988
    Website: http://www.acceleronpharma.com

    Index Membership:N/A
    Full Time Employees:83

    Business Summary 

    Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. The company is developing luspatercept and sotatercept therapeutic candidates, which are in Phase 3 clinical trials used to treat anemia and associated complications in patients with ß-thalassemia and myelodysplastic syndromes. The sotatercept therapeutic candidate is also used to increase bone mineral density; and to treat the final stage of chronic kidney disease and end-stage renal disease. It is also developing dalantercept therapeutic candidate to treat renal cell carcinoma and hepatocellular carcinoma; and ACE-083 that is in Phase 1 clinical trial used to promote muscle growth and function in specific treated muscle groups. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Acceleron Pharma, Inc.

    Corporate Governance 
    Acceleron Pharma, Inc.’s ISS Governance QuickScore as of Apr 1, 2015 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 9; Compensation: 3.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. John L. Knopf Ph.D., 63
    Founder, Chief Exec. Officer, Pres and Director
    Dr. Thomas P. Maniatis Ph.D., 72
    Co-Founder, Chairman of Scientific Advisory Board, Director and Member of Compensation Committee
    Dr. John D. Quisel J.D., Ph.D., Esq., 44
    Sr. VP and Gen. Counsel
    Dr. Matthew L. Sherman M.D., 59
    Chief Medical Officer and Exec. VP
    Dr. Mark Ptashne Ph.D.,
    Co-Founder and Member of Scientific Advisory Board
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders